Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NNMT | P40261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23538185 | 0.88 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL15565594 | 0.86 | MAPK1 (0.53) | MAPK1KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL23537880 | 0.86 | MAPK1 (0.56) | MAPK1KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL19590814 | 0.84 | MAPK1 (0.54) | MAPK1KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL11547773 | 0.83 | GABRA5 (0.48) | NNMTMAPTGABRA5 | |
| SCHEMBL21394819 | 0.82 | MAPT (0.70) | MAPK1KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL11551255 | 0.82 | NNMT (0.62) | KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL31215048 | 0.81 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL23537708 | 0.81 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1NNMTMAPT | |
| SCHEMBL28738097 | 0.81 | MAPK1 (0.50) | MAPK1KDM4EL3MBTL1NNMTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| CN-101184731-A | Indoline compounds | FOURNIER LAB SA (FR) | 2008-05-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | MAPK1 870/4885KDM4E 1574/4885L3MBTL1 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.